Results 231 to 240 of about 42,703 (308)

Major adverse cardiovascular events or venous thromboembolism in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a nationwide, population-based cohort study. [PDF]

Ther Adv Musculoskelet Dis
Kao CM, Chen YJ, Chen YM, Chen DY, Chen HH.   +4 more
europepmc   +1 more source

Effect of Comedication With Conventional Synthetic Disease‐Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study

, 2016
Alexandre Sepriano, Sofía Ramiro, Désirée van der Heijde, Pedro Ávila-Ribeiro, R. Fonseca, J. Borges, L. Teixeira, P. Carvalho, Marcos Cerqueira, Joana Sousa‐Neves, T. Meirinhos, Anabela Barcelos, Graça Sequeira, Maria João Salvador, J. Canas da Silva, Helena Santos, Miguel Bernardes, Elsa Vieira‐Sousa, Helena Canhão, Jaime Branco, Fernando Pimentel‐Santos, Robert Landewé   +21 more
openalex   +1 more source

Comparative Effectiveness and Safety of the JAK Inhibitors and Biologic Disease-Modifying Antirheumatic Drugs in Treating Children With Nonsystemic Juvenile Idiopathic Arthritis: A Bayesian Meta-Analysis of Randomized Controlled Trials. [PDF]

ACR Open Rheumatol
Li Y, Huang B, Andorf S, Yue X, Lovell DJ, Brunner HI.   +5 more
europepmc   +1 more source

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation

, 2016
Matt Stevenson, Rachel Archer, Jonathan Tosh, Emma Simpson, Emma Everson-Hock, John Stevens, Mónica Hernández Alava, Suzy Paisley, Kath Dickinson, David L. Scott, Adam Young, Allan Wailoo   +11 more
openalex   +2 more sources

Effectiveness of JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs on Pain Reduction in Rheumatoid Arthritis: Results From a Nationwide Swedish Cohort Study. [PDF]

Arthritis Rheumatol
Eberhard A, Di Giuseppe D, Askling J, Bergman S, Bower H, Chatzidionysiou K, Forsblad-d'Elia H, Kastbom A, Olofsson T, Frisell T, Turesson C.   +10 more
europepmc   +1 more source

A case of essential thrombocythemia and ankylosing spondylitis treated with a combination of anagrelide, disease-modifying antirheumatic drugs, and etanercept

, 2016
Vanja Zeremski, Aleksandar Savić, Tatjana Ilić, Ivana Milošević, Marina Maksimovic, Biljana Vučković   +5 more
openalex   +2 more sources

N-terminal pro-brain natriuretic peptide levels and diastolic dysfunction in patients with early rheumatoid arthritis before the administration of disease-modifying antirheumatic drugs

, 2016
I. G. Kirillova, Д. С. Новикова, Т. В. Попкова, Е Н Александрова, А. А. Новиков, Yu. N. Gorbunova, E. I. Markelova, Yu. O. Korsakova, С. И. Глухова, А. В. Волков, Е. Л. Лучихина, Н. В. Демидова, К. А. Касумова, С А Владимиров, M. A. Kanonirova, GV Lukina, Д. Е. Каратеев, E L Nasonov   +17 more
openalex   +1 more source

Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis. [PDF]

Korean J Intern Med
Lee BW, Lee JJ, Kim WU.
europepmc   +1 more source

Predictors at diagnosis for start of biologic disease-modifying antirheumatic drugs in patients with early rheumatoid arthritis: a cohort study. [PDF]

BMJ Open
Hameed M, Exarchou S, Eberhard A, Sharma A, Bergström U, Cagnotto G, Einarsson JT, Turesson C.   +7 more
europepmc   +1 more source